IN8bio, Inc. INAB
As ofNov 20, 2026, 11:31 AM EST
- YTD
- -67.05%
- 1 year
- -51.51%
5D -0.0486 (-5.92%)
- Market cap
- 8.50M
- EPS (ttm)
- -1.00
- Shares out
- 72.48M
- Forward P/E
- -0.80
- YTD return
- -67.05%
- 1-year return
- -51.51%
- 50-day average
- 0.3045
- 200-day average
- 0.70842
- Enterprise value
- 12.05M
- Volume
- 7.76K
- Avg volume
- 121.68K
- Open
- 0.7863
- Previous close
- 0.7724
- Day's range
- 0.7863 – 0.7863
- 52-week range
- 0.724 – 2.73
- Beta
- -0.07
- Analysts
- Buy
- Price target
- 4.75 (+516.1%)
Key statistics
- Price / book
- 0.42
- Free cash flow
- -12.41M
- Total cash
- 10.22M
- Total debt
- 5.90M
- Return on equity
- -180.45%
- Short % of float
- 1.83%
Fundamental scorecard
5 of 25 checks passed on INAB’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.14 | -0.15 | -0.01 | -7.14% |
| Aug 8, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.16 | -0.19 | -0.03 | -18.75% |
| May 9, 2024 | Mar 1, 2024 | -0.17 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.17 | -0.20 | -0.03 | -17.65% |
| Mar 14, 2024 | Dec 1, 2023 | -0.16 | -0.21 | -0.05 | -31.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2024 | Jones Trading | down | Buy | Hold |
| Jun 14, 2024 | Jones Trading | main | Buy | Buy |
| Jun 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- in8bio.com
News
12 Health Care Stocks Moving In Monday's After-Market Session IN8bio Presents Updated Clinical Data From INB-200 And INB-400 Programs In Newly Diagnosed GBM, In Oral Session At 2026 SNO Annual Meeting
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
Your note
Sign in to keep a note on INAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRANDT PETER C | Director | Stock Award(Grant) | Oct 3, 2024 | 622,894 |
| EPPERLY CORINNE | Director | Stock Award(Grant) | Dec 12, 2023 | 81,967 |
| GOSWAMI TRISHNA | Officer | Stock Award(Grant) | Dec 12, 2023 | 6,729 |
| GRAFF JEREMY R. | Director | Stock Award(Grant) | Dec 12, 2023 | 4,549 |
| HO WILLIAM TAI WEI | Chief Executive Officer | Stock Award(Grant) | Oct 3, 2024 | 2,803,590 |
| LAMB LAWRENCE S. | Officer | Stock Award(Grant) | Dec 12, 2023 | 101,369 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 2.31% | 1,674,638 | 401.91K | Sep 29, 2024 |
| Vanguard Group Inc | 1.96% | 1,423,897 | 341.74K | Sep 29, 2024 |
| 683 Capital Management LLC | 1.86% | 1,350,304 | 324.07K | Sep 29, 2024 |
| Sigma Planning Corp | 1.17% | 851,280 | 204.31K | Sep 29, 2024 |
| Ensign Peak Advisors, Inc | 1.14% | 829,176 | 199.00K | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 0.60% | 434,809 | 104.35K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.31% | 952,487 | 228.60K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.65% | 471,410 | 113.14K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.24% | 173,058 | 41.53K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 61,228 | 14.69K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.07% | 51,554 | 12.37K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 36,345 | 8.72K | Oct 30, 2024 |
